The DOI matches its Crossref record.
Steroid‐sparing effects of methotrexate in systemic lupus erythematosus: A double‐blind, randomized, placebo‐controlled trial
Abstract
Objective: To assess the potential benefits of methotrexate in patients with systemic lupus erythematosus (SLE). Methods: A 12‐month, double‐blind, placebo‐controlled trial of methotrexate with folic acid was conducted. Intent‐to‐treat analyses were performed with mixed linear models and α = 0.04 (96% confidence interval [96% CI]) to account for interim analysis of longitudinal data to assess the treatment effects on lupus disease activity and daily steroid dose across monthly measurements, and to test if the treatment effects depended on selected participant characteristics. Results: Of 215 participants screened, 94 were excluded, 35 declined, and 86 were randomized (methotrexate = 41, placebo = 45). The groups were balanced for demographic and disease characteristics. Antimalarial use was more frequent in the placebo group, which was adjusted for in multivariable analyses. Sixty participants (27 methotrexate, 33 placebo) completed the study and 26 terminated early. Among participants who had the same baseline prednisone dose, those taking methotrexate received, on average, 1.33 mg/day less prednisone during the trial period (96% CI 0.06, 2.72 mg/day; a 22% reduction of their average‐during‐trial daily dose) compared with those in the placebo group. For the primary measure of disease activity (revised Systemic Lupus Activity Measure), methotrexate use was also associated with a marginally significant reduction in the mean during‐trial score of 0.86 units (96% CI 0.01, 1.71; P = 0.039). A significant interaction between treatment and baseline damage was found (P = 0.001). Conclusion: Methotrexate conferred a significant advantage in participants with moderately active lupus by lowering daily prednisone dose and slightly decreasing lupus disease activity. As a therapeutic option in moderate SLE, methotrexate can be considered to be steroid sparing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Kiriakidou, M., & Ching, C. L. (2020) · Annals of Internal Medicine · doi:10.7326/aitc202006020 · Cited by 821
Systemic lupus erythematosus: Diagnosis and clinical management
Fava, A., & Petri, M. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.11.001 · Cited by 754
Management strategies and future directions for systemic lupus erythematosus in adults
Durcan, L., O'Dwyer, T., & Petri, M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30237-5 · Cited by 648
Novel paradigms in systemic lupus erythematosus
Dörner, T., & Furie, R. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30546-x · Cited by 565
Psoriasis: Which therapy for which patient
Kaushik, S. B., & Lebwohl, M. G. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.06.057 · Cited by 368
Metadata
- Authors
- Fortin, P. R., Abrahamowicz, M., Ferland, D., Lacaille, D., Smith, C. D., Zummer, M., & Canadian Network For Improved Outcomes in Systemic Lupus Erythematosus
- Venue
- Arthritis Care & Research
- Publisher
- Wiley
- Published
- 2008-11-26
- Volume
- 59
- Issue
- 12
- Pages
- 1796-1804
- ISSN
- 0893-7524 (ISSN-L)
- 1529-0123
- OpenAlex
- W2016157833
- Cited by
- 165
- References
- 0
- FWCI
- 5.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Steroid‐sparing effects of methotrexate in systemic lupus erythematosus: A double‐blind, randomized, placebo‐controlled trial. https://app.cochat.ai/papers/10.1002/art.24068
- The paper
- Fortin, P. R., Abrahamowicz, M., Ferland, D., Lacaille, D., Smith, C. D., Zummer, M., & Canadian Network For Improved Outcomes in Systemic Lupus Erythematosus. (2008). Steroid‐sparing effects of methotrexate in systemic lupus erythematosus: A double‐blind, randomized, placebo‐controlled trial. Arthritis Care & Research. https://doi.org/10.1002/art.24068
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.